HRP20050245A2 - Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia - Google Patents

Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia Download PDF

Info

Publication number
HRP20050245A2
HRP20050245A2 HR20050245A HRP20050245A HRP20050245A2 HR P20050245 A2 HRP20050245 A2 HR P20050245A2 HR 20050245 A HR20050245 A HR 20050245A HR P20050245 A HRP20050245 A HR P20050245A HR P20050245 A2 HRP20050245 A2 HR P20050245A2
Authority
HR
Croatia
Prior art keywords
epa
use according
acid
treatment
bulimia
Prior art date
Application number
HR20050245A
Other languages
English (en)
Croatian (hr)
Inventor
Frederick Horrobin David
Ayton Agnes
Original Assignee
Laxdale Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050245(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Limited filed Critical Laxdale Limited
Publication of HRP20050245A2 publication Critical patent/HRP20050245A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HR20050245A 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia HRP20050245A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
HRP20050245A2 true HRP20050245A2 (en) 2005-10-31

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050245A HRP20050245A2 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20070082949A1 (en) * 2003-11-14 2007-04-12 Hiroaki Ootani Agent for preventing and treating language disorders
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101430214B1 (ko) 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
DK2121576T3 (en) 2007-02-15 2016-02-15 Ct De Rech Sur Les Biotechnologies Marine Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
LT2443246T (lt) * 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
CN103354839A (zh) * 2011-02-11 2013-10-16 纳幕尔杜邦公司 二十碳五烯酸浓缩物
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
AU2019217673A1 (en) 2018-02-07 2020-09-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
ES2992095T3 (es) 2018-05-03 2024-12-09 Scf Pharma Inc Monoglicéridos de ácidos grasos poliinsaturados, composiciones y uso de los mismos para modular la composición de la microbiota de un sujeto
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4125836A1 (en) * 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
MXPA05002943A (es) 2005-06-03
TW200410682A (en) 2004-07-01
RU2330653C2 (ru) 2008-08-10
KR20050042823A (ko) 2005-05-10
US20060135608A1 (en) 2006-06-22
CA2499142A1 (en) 2004-03-25
RU2005107416A (ru) 2006-01-20
EP1556028A1 (en) 2005-07-27
RS20050226A (sr) 2007-09-21
PL375726A1 (en) 2005-12-12
AU2003269138A1 (en) 2004-04-30
NO20051847L (no) 2005-04-15
WO2004024136A1 (en) 2004-03-25
IS7744A (is) 2005-03-15
CN1694694A (zh) 2005-11-09
BR0317857A (pt) 2005-12-06
GB0221480D0 (en) 2002-10-23
ZA200502161B (en) 2005-09-15
JP2006503031A (ja) 2006-01-26
NZ538793A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
HRP20050245A2 (en) Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia
Drabińska et al. Recent advances in the application of a ketogenic diet for obesity management
Canani et al. Short-and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
EP2124977A1 (en) Method for treating or preventing systemic inflammation
EP2214683A2 (en) Unit dosage for brain health
Jiang et al. The effects of two mixed intravenous lipid emulsions on clinical outcomes in infants after gastrointestinal surgery: a prospective, randomized study
US6753350B1 (en) Method to reduce the incidence of intraventricular hemorrhage in preterm infants
WO2017176199A1 (en) A macronutrient composition for use in a method for treatment of gestational diabetes
WO2022210856A1 (ja) 睡眠の質を改善するための組成物
CN115315199A (zh) 用于抑制认知功能下降和/或改善认知功能的组合物
Lee et al. Association between multioil intravenous lipid emulsion and cholestasis in infants with gastrointestinal disorders: A retrospective cohort study
CN100512819C (zh) 无糖维生素口服液
Noland Lipidomics: Clinical Application
US6482434B1 (en) Method for reducing adverse effects of a weight loss regimen
Turusheva Nutrition strategy for patients under conditions of the coronavirus infection pandemic (SARS-COV-2)
RU2338543C2 (ru) Способ комплексного лечения терапевтически резистентных реактивных депрессий
Rahardjo et al. Formulating Diet for Transitional Feeding in Tuberculous Meningitis Patient during Hospital Care and through to Period of Home Healthcare
CN118844506A (zh) 适用于妊娠期糖尿病营养干预的固体脂质组合物
JP6281919B2 (ja) 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤
Pelekhaty et al. Nutritional Management of the Trauma Patient
Sijben et al. Is it prudent to add n-3 long-chain polyunsaturated fatty acids to paediatric enteral tube feeding?
CN115776884A (zh) 增加肠道微生物群系中的戴阿利斯特杆菌属种的群体的方法
Escott-Stump THEME THREE Homeostasis and Regulation
JP2023525712A (ja) 認知機能を改善するためのｍｃｔ製剤

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080916

Year of fee payment: 6

OBST Application withdrawn